Introduction
============

Aberrant methylation in the promoter-CpG islands of tumor suppressor genes (TSGs) is one of the most epigenetic alterations that involves in tumorigenesis and cancer progression. Several studies have reported that the methylation of TSGs such as SOCS-1, APC, E-cadherin, GSTP, p15, p16, RAR-, p14, and p73 genes leads to silenced genes resulting in HCC^[@B1]^. The DNA methylation process is catalyzed by DNA methyltransferases (DNMTs). The mammalian DNMTs are encoded by three distinct families of DNMT genes including DNMT1, DNMT2, and DNMT3. These enzymes catalyze the transfer of the methyl groups to DNA and methylate the CpG islands of TSGs. Increased expression of DNMT1, DNMT3a, and DNMT3b mRNA has been reported in HCC^[@B2]^. Additionally, histone [deacetylation](https://www.sciencedirect.com/topics/medicine-and-dentistry/deacetylation) regulates [chromatin remodeling](https://www.sciencedirect.com/topics/medicine-and-dentistry/chromatin-remodeling) and down-regulates TSGs in many types of [cancer cells](https://www.sciencedirect.com/topics/medicine-and-dentistry/cancer-cell). Overexpression of [histone deacetylase](https://www.sciencedirect.com/topics/medicine-and-dentistry/histone-deacetylase) 1 (HDAC1) has been indicated in HCC^[@B3]^. The reversion of two epigenetic processes, hypermethylation and deacetylation by epi-drugs can restore normal expression of TSGs. It has been demonstrated that DNA mehyltransferase inhibitors such as 5-azacytidine (5-aza-CR, Vidaza), 5-aza-2′-deoxycytidine (5-aza-dC, Dacogen), and Zebularine (1-(β-~D~-ribofuranosyl)-1, 2-dihydropyrimidin-2-one) can restore hypermethylated TSGs resulting in apoptosis induction in several cancers, including HCC (HepG2, Hep3B, and Hepa1-6), renal, colon, and lung cancer cells ^[@B4],[@B5]^. [HDAC inhibitors](https://www.sciencedirect.com/topics/medicine-and-dentistry/histone-deacetylase-inhibitor) (HDACIs) can induce [cell-cycle arrest](https://www.sciencedirect.com/topics/medicine-and-dentistry/cell-cycle-arrest) and cell apoptosis. Apoptotic effect of HDACIs such as butyrate, suberoylanilide hydroxamic acid (SAHA), depsipeptide, and MS-275 has been shown in various cancers such as colon cancer^[@B6]^, breast cancer, non--small-cell lung cancer (NSCLC), ovarian cancer^[@B7]^, and HCC (HepG2, MH1C1, Hepa1--6 and Hep1B)^[@B8]^.

Previously, we reported that 5-aza-2′-deoxycytidine (5-AZA-CdR) and VPA can inhibit DNMT1 and induce apoptosis in HCC WCH-17 cell line ^[@B9]^. This result encouraged us to investigate the effect of 5-aza-2′-deoxycytidine (5-AZA-CdR) in combination with and in comparison to vorinostat (Suberoylanalide hydroxamic acid, SAHA) on DNMT1, DNMT3a, DNMT3b, [histone deacetylase](https://www.sciencedirect.com/topics/medicine-and-dentistry/histone-deacetylase) 1 (HDAC1) glutathione S-transferase 1 (GSTP1) and suppressor of cytokine signaling 1 (SOCS1) genes expression, cell growth inhibition and apoptotic induction in hepatocellular LCL-PI 11 cell line in the present study.

MATERIALS AND METHODS
=====================

**Materials**

Human HCC LCL-PI 11 cells were purchased from the National Cell Bank of Iran-Pasteur Institute and maintained in Dulbecco's modified Eagle's medium (DMEM), containing 100 mL/L fetal bovine serum and antibiotics at 37º C in a humidified atmosphere. 5-AZA-CdR and SAHA were purchased from Sigma (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide (DMSO; Sigma) at a final concentration of 100 μM in order to prepare a working stock solution. All other necessary concentrations were provided by diluting this solution.

Phosphate-buffered saline (PBS), 3-\[4, 5-dimethyl-2-thiazolyl\]-2, 5-diphenyl-2H-tetrazolium bromide (MTT), Trypsin-EDTA, DMSO, DMEM, Annexin-V-(FITC), propidium iodide (PI), streptomycin, and penicillin were purchased from Sigma. Real-time polymerase chain reaction (PCR) kits (qPCR MasterMix Plus for SYBR Green I dNTP) and total RNA extraction kit (TRIZOL reagent) were obtained from Applied Biosystems Inc. (Foster, CA, USA).

**Cell culture and cell viability**

The cells were seeded and cultured with DMEM (pH 7.2--7.4) supplemented with sodium pyruvate, sodium bicarbonate, 10% FBS, and antibiotics at 37°C in 5% CO2 overnight. Then, the cells were plated into 96-well plates at a density of 5 × 10^5^live cells per well. After one day, the cells were treated with medium, containing various concentrations of 5-Aza-CdR (1, 2.5, 5, 7.5 and 10 μM) and SAHA (1, 2.5, 5, 7.5 and 10 μM) for 24h and 48h. After treatment times, the effect of 5-Aza-CdR and SAHA was assessed by MTT assay according to

Standard protocols. In this regard, the culture medium was removed, the cells were washed twice with PBS and a fresh medium containing 0.5 mg/mL MTT was added. After 4 h incubation, the formazan crystals were dissolved in DMSO and the absorbance was measured by a microplate reader at a wavelength of 570 nM. Each experiment was repeated three times (triplicates).

**Cell apoptosis assay**

To assess the apoptotic cells by flow cytometry, the cells were plated (at a density of 5 × 10^5^) in 24-well and treated with 5-Aza-CdR (2.5 μM) and SAHA (2.5 μM) according to IC50, for 24 and 48 h. The control groups were incubated with DMSO only. After treatment, all the adherent cells were harvested by trypsinization and the single cell suspension was prepared. After centrifugation, the cells were washed with cold phosphate-buffered saline (PBS) and resuspended in Binding buffer (1x). For detection of apoptotic cells, annexin-V-(FITC) and propidium iodide (PI) were used according to the manufacturer\'s protocol. After incubation, the samples were subjected to flow cytometry and the apoptotic cells were counted by FACS can flow cytometry (Becton Dickinson, Heidelberg, Germany).

**Real-Time quantitative reverse transcription polymerase chain reaction**

**(qRT-PCR) analysis**

Real-time quantitative RT-PCR (qRT-PCR) was performed with the SYBR Green QuantiTect RT-PCR Kit (Qiagen) according to the manufacturer\'s instructions. To determine whether 5-Aza-CdR and SAHA could affect DNMT1, DNMT3a, DNMT3b, HDAC1, GSTP1and SOCS1 genes expression qRT-PCR was performed. The cells were treated with Aza-CdR and SAHA based on IC5o values, and total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA and treated by RNase‑free DNase (Qiagen) to eliminate the genomic DNA before cDNA synthesis. By using the RevertAid™ First Strand cDNA Synthesis Kit, total RNA was reverse transcribed to complementary DNA (cDNA) using oligodT primers and Superscript II Reverse Transcriptase according to the protocol. Real-time RT-PCR reactions for cDNA amplification were performed as mentioned previously^[@B10]^. The primer sequences are shown in [Table 1](#T1){ref-type="table"}. Quantitative RT-PCRs were performed using a Step One Real Time PCR System (Applied Biosystems). Thermal cycling conditions was : an initial denaturation at 95 ˚ C for 10 minutes, followed by 40 cycles of denaturation at 95˚ C for 20 seconds, annealing at 58 ˚c for 15 seconds and extension at 72 ˚ C for 15 seconds . GAPDH was used as an endogenous control. Data were analyzed using the comparative Ct (ΔΔct) method.

The amount of target, normalized to the endogenous reference. The relative expression was calculated with the "delta-delta Ct method" (DDCt = DCtsample DCtcalibrator). The Ct (threshold cycle) values were normalized against the endogenous reference gene and were compared with the calibrator. Considering that DDCt validation required equal efficiencies of target genes and reference amplification, standard curve assays were obtained for target gene and reference.

###### 

Primer sequences used in the present study

  --------------------------------------------------------------------
  **Primer name**   **Primer sequences (5' to 3')**    **Reference**
  ----------------- ---------------------------------- ---------------
  DNMT1 Forward\    GAG GAA GCT GCT AAG GAC TAG TTC\   10
  DNMT1 Reverse     ACT CCA CAA TTT GAT CAC TAA ATC    

  DNMT3a Forward\   GGA GGC TGA GAA GAA AGC CAA GGT\   10
  DNMT3a Reverse    TTT GCC GTC TCC GAA CCA CAT GAC    

  DNMT3b Forward\   TAC ACA GAC GTG TCC AAC ATG GGC\   10
  DNMT3b Reverse    GGA TGC CTT CAG GAA TCA CAC CTC    

  GSTP1 Forward\    AGTTGCGCGGCGATTTC\                 11
  GSTP1 Reverse     GCCCCAATACTAAATCACGACG             

  SOCS1 Forward\    CGCGCGGGGTTTTCGTAGTA\              11
  SOCS1 Reverse     CTAACTCCAACCGTCCGACC               

  HDAC1 Forward\    AGACAGCTGTGGCCCTGGATAC\            12
  HDAC1 Reverse     CGGCAGCATTCTAAGGTTCTCAA            
  --------------------------------------------------------------------

**Statistical analysis**

The database was setup with the SPSS 16.0 software package (SPSS Inc., Chicago, Illinois, USA) for analysis. The data were acquired from three tests and are shown as means ± standard deviations. Statistical comparisons between groups were performed with ANOVA (one‑way ANOVA) and Turkey test. A significant difference was considered as P \< 0.05.

Results
=======

**Result of cell viability by the MTT assay**

The LCL-PI 11 cells were treated with various doses of 5-Aza-CdR and SAHA for 24h and 48h as mentioned above, while control cells were received 0.05% DMSO. Then, the cell viability was determined by using the MTT assay. As shown in [Figure 1](#F1){ref-type="fig"}, both agents indicated significant inhibitory effect with all concentrations (P\< 0.001) in a dose and time-dependent manner. IC50 values were obtained with approximately 2.5 μM of 5-Aza-CdR and 2.5 μM of SAHA.

**Result of** **cell apoptosis assay**

To determine whether 5-Aza-CdR and SAHA could induce apoptosis, we stained the cells using annexin-V-(FITC) and propidium iodide (PI). As mentioned above, the cells were treated with 5-Aza-CdR (2.5 μM) and SAHA (2.5 μM) for different time periods (24 and 48 h) and then collected after trypsinization and stained with Annexin V

and propidium iodide following which investigated by flow cytometry. As shown in [Figure 2](#F2){ref-type="fig"}, we observed a significant increase in the number of apoptotic cells in all treated groups. The percentage of apoptotic cells was 11.41 %, and 20.54 % after treatment with 5-Aza-CdR and 21% and 52.54 % after treatment with SAH and after 24 and 48h, respectively (P \< 0.01). The apoptotic effect of SAHA was more than that of 5-Aza-CdR. Besides, maximal apoptosis was observed in the combined treatment groups as indicated in [Figure 3](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}.

**Result of determination of genes expression**

The effect of 5-Aza-CdR (2.5 μM) and SAHA (2.5 μM) on DNMT1, DNMT3a, DNMT3b, HDAC1, GSTP1and SOCS1 genes expression was evaluated by quantitative real-time RT-PCR analysis at different time periods, including 24 and 48 h. The result indicated that 5-Aza-CdR decreased DNMT1, DNMT3a, DNMT3b and increased GSTP1and SOCS1 genes expression significantly. Besides, SAHA decreased HDAC1 and increased GSTP1 and SOCS1 genes expression significantly as demonstrated in [Figure. 4](#F4){ref-type="fig"} and [Table 3](#T3){ref-type="table"}. Meanwhile, SAHA had a more strong effect on the GSTP1and SOCS1 gene expression in comparison to 5-Aza-CdR. Additionally, maximal expression of GSTP1 and SOCS1 was seen with combined treatment.

![The effect of 5-AZA-CdR and SAHA on viability of LCL-PI 11.](IJHOSCR-14-45-g001){#F1}

![The apoptosis-inducing effect of 5-AZA-CdR and SAHA was investigated by flow cytometric analysis of HCC LCL-PI 11cells stained with Annexin V and propidium iodide. Result of flow cytometry indicated that both compounds induced cell apoptosis significantly. As indicated above, SAHA had more strong effect on apoptosis induction that than of SAHA. Asterisks (\*) indicate significant differences between treated cells and the control groups.](IJHOSCR-14-45-g002){#F2}

![The apoptosis‑inducing effect of 5-AZA-CdR incombination to SAHA was investigated by flow cytometric analysis of HCC LCL-PI 11cells stained with Annexin V and propidium iodide. Result of flow cytometry indicated that combined treatment induced significant cell apoptosis more than each agent alone. Asterisks (\*) indicate significant differences between treated cells and the control groups.](IJHOSCR-14-45-g003){#F3}

![The relative expression level of DNMT1, DNMT3a, DNMT3b, and HDAC1 in response to 5-AZA-CdR and SAHA.](IJHOSCR-14-45-g004){#F4}

###### 

The percentage of apoptotic cells treated with 5-Aza-CdR and SAHA.

  **Drug**    **Dose (μM )**   **Duration (h)**   **Apoptosis (%)**   **P**
  ----------- ---------------- ------------------ ------------------- -------
  5-Aza-CdR   2.5              24                 11.41               0.001
  5-Aza-CdR   2.5              48                 20.54               0.001
  SAHA        2.5              24                 21.51               0.001
  SAHA        2.5              48                 52.54               0.001
  Combined    2.5/2.5          24                 65.85               0.001
  Combined    2.5/2.5          48                 93.1                0.001

![The relative expression level of GSTP1 AND SOCS1 in response to 5-AZA-CdR and SAHA (individually and combined).](IJHOSCR-14-45-g005){#F5}

###### 

The relative expression level of DNMT1, DNMT3a, DNMT3b, GSTP1and SOCS1 genes expression

  **Gene**   **Drug**    **Dose (μM)**   **Duration (h)**   **Expression**   **P**
  ---------- ----------- --------------- ------------------ ---------------- -------
  DNMT1      5-Aza-CdR   2.5 μM          24                 0.65             0.011
  DNMT3a     5-Aza-CdR   2.5 μM          24                 0.61             0.005
  DNMT3b     5-Aza-CdR   2.5 μM          24                 0.56             0.002
  DNMT1      5-Aza-CdR   2.5 μM          48                 0.47             0.005
  DNMT3a     5-Aza-CdR   2.5 μM          48                 0.42             0.002
  DNMT3b     5-Aza-CdR   2.5 μM          48                 0.34             0.001
  GSTP1      5-Aza-CdR   2.5 μM          24                 1.7              0.001
  GSTP1      5-Aza-CdR   2.5 μM          48                 1.9              0.001
  SCOS1      5-Aza-CdR   2.5 μM          24                 1.8              0.001
  SCOS1      5-Aza-CdR   2.5 μM          48                 2.2              0.001
  HDAC1      SAHA        2.5 μM          24                 0.45             0.003
  HDAC1      SAHA        2.5 μM          48                 0.28             0.003
  GSTP1      SAHA        2.5 μM          24                 2.1              0.001
  GSTP1      SAHA        2.5 μM          48                 2.5              0.001
  SCOS1      SAHA        2.5 μM          24                 2.3              0.001
  SCOS1      SAHA        2.5 μM          48                 2.7              0.001
  GSTP1      Combined    2.5 μM/2.5 μM   24                 2.9              0.001
  GSTP1      Combined    2.5 μM/2.5 μM   48                 3                0.001
  SCOS1      Combined    2.5 μM/2.5 μM   24                 3.1              0.001
  SCOS1      Combined    2.5 μM/2.5 μM   48                 3.4              0.001

Discussion
==========

Several TSGs have been demonstrated to be silenced in human cancers. In fact, the silencing is accompanied by epigenetic alterations of histone deacetylation and DNA hypermethylation of the promoter regions of TSGs. Aberrant DNA methylation and histone deacetylation of these genes have been reported in HCC ^[@B13],[@B14]^. Fortunately, epigenetic alterations are reversible and could be modified in response to DNMT and HDAC inhibitors. Because histone deacetylation and DNA methylation are the two best-characterized covalent modifications associated with chromatin compaction and silenced TSGs, we focused our attention on these changes. In the present study, we indicated that DNMT inhibitor 5-AZA-CdR and histone deacetylase inhibitor SAHA re-activate GSTP1 and SOCS1 gene expression epigenetically. We reported that these compounds up-regulate GSTP1 and SOCS1 gene expression by down-regulation of DNMT1, DNMT3a, DNMT3b, and HDAC1, resulting in cell growth inhibition and apoptosis induction. Furthermore, we demonstrated that SAHA had a more strong effect on GSTP1 and SOCS1 gene expression than that of 5-AZA-CdR. Besides, maximal GSTP1 and SOCS1 genes expression and apoptotic induction were seen after combined treatment. Consistent with our findings, hypermethylation of numerous TSGs have been reported in HCC, including GSTP1, SOCS-1, RASSF1A, APC, p16, MGMT, DAPK, and RIZ1 ^[@B15]^. Another study has been indicated that GSTP1, CCND2, RASSF1A, SPINT2, APC, RUNX3, and CFTR are aberrantly methylated in HCC ^[@B16]^. There are similar reports about p16 (INK4a), p15 (INK4b) ^[@B17]^, GSTP1 in HCC Hep3B, HepG2 ^[@B18]^, and GSTP1 in HCC Hep3B^[@B19]^. In addition to hypermethylation, we indicated that HDAC1 activity is one of the most characterized causes of HCC. In line with our findings, high HDAC1 expression has been shown in this cancer^[@B20]^. Other researchers have been reported overexpression of various HDACs in HCC, including HDAC2 in Hep3B cells^[@B21]^, HDAC5^[@B22]^, HDAC6 ^[@B23],[@B24]^, and HDAC8 ^[@B25]^. As we indicated in this study, several lines of evidence have been reported that 5-AZA-CdR can re-express GSTP1 by demethylation in prostate cancer^[@B26]^ and gastric cancer ^[@B27]^. In addition to 5-AZA-CdR, other DNMTIs can re-activate GSTP1 in prostate cell lines (PC-3, DU-145, LNCaP)^[@B28]^. Similarly, it has been shown that 5-AZA-CdR can re-activate SOCS1 expression in breast cancer cells^[@B29]^. We showed that SAHA up-regulated GSTP1 and SOCS1 through HDAC1 down-regulation. Consistent with this observation**,**another study demonstrated that SAHA inhibits HDAC1 by which increases p19^INK4d^ and p21^Waf1/Cip1^ expression and apoptosis induction in HCC ^[@B30]^. Similar inhibition has been reported in MEL cells ^[@B31]^. We observed maximal expression of GSTP1 and SOCS1 after combined treatment with 5-AZA-CdR and SAHA. Consistent with our observation, it has been concluded that the combination therapy of DNMTIs and histone deacetylase inhibitor shows synergistic anticancer effect^[@B32]^. Other researchers have been reported that GE in combination with trichostatin A (TSA) significantly increases TNFR-1 gene expression and apoptosis induction in lung cancer A549 cell line^[@B33]^. Previously, we demonstrated that GE and TSA can significantly reactivate the estrogen receptor alpha (ERα) gene and play a significant role in apoptosis induction in HCC ^[@B34]^. With regard to our previous results and the results of other researchers mentioned above, it is obvious that none of the studies have shown the effect of 5-AZA-CdR and SAHA (individually and combined) on GSTP1 and SOCS1 gene expression as a mechanism of apoptosis induction. Therefore, it is a novelty of our work. It should be noted that the effect of 5-AZA-CdR on GSTP1 and SOCS1 re-activation is one of the several mechanisms of this agent on apoptosis induction. Other pathways include down-regulation of anti-apoptotic XIAP, cIAP-1, Bcl-2, and cIAP-2 protein levels, the activation of caspases, the cleavage of Bid proteins, and the collapse of mitochondrial membrane potential (MMP) ^[@B35]^. Besides, there are many mechanisms of the antiapoptotic effect of HDACIs in addition to HDAC1 inhibition. The mechanisms by which these compounds induce apoptosis involving the accumulation of acetylated forms of histones and non‐histone protein substrates.

There is evidence that indicates that certain HDACIs may selectively inhibit different HDACs (e.g. TSA is a potent inhibitor of HDACs 1, 3, and 8)^[@B36]^. Although, we reported two epigenetic causes of HCC including hypermethylation and deacetylation of TSGs GSTP1 and SOCS1 we didn't evaluate protein expression status of these genes in the current study. Therefore, protein expression evaluation is recommended.

CONCLUSION
==========

5-AZA-CdR and SAHA down-regulated DNMT1, DNMT3a, DNMT3b, and HDAC1 and up-regulated GSTP1 and SOCS1 gene expression by which inhibited cell viability and induced apoptosis, suggesting that they could be used in the treatment of HCC.

This article was supported by adjutancy of research of Jahrom Medical University-Iran. This article has been extracted from Ms. Zahra Esmi's thesis.

CONFLICT OF INTEREST
====================

The authors report no conflict of interest.
